Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Do we need a Global Virome Project?

Jonas O, Seifman R.

Lancet Glob Health. 2019 Oct;7(10):e1314-e1316. doi: 10.1016/S2214-109X(19)30335-3. No abstract available.

2.

An interventional image-guided microdevice implantation and retrieval method for in-vivo drug response assessment.

Bhagavatula SK, Upadhyaya K, Miller BJ, Bursch P, Lammers A, Cima MJ, Silverman SG, Jonas O.

Med Phys. 2019 Sep 8. doi: 10.1002/mp.13803. [Epub ahead of print]

PMID:
31494942
3.

Pandemic bonds: designed to fail in Ebola.

Jonas O.

Nature. 2019 Aug;572(7769):285. doi: 10.1038/d41586-019-02415-9. No abstract available.

PMID:
31409936
4.

VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells.

Patterson JC, Joughin BA, Prota AE, Mühlethaler T, Jonas OH, Whitman MA, Varmeh S, Chen S, Balk SP, Steinmetz MO, Lauffenburger DA, Yaffe MB.

Cell Syst. 2019 Jul 24;9(1):74-92.e8. doi: 10.1016/j.cels.2019.05.009. Epub 2019 Jul 10.

5.

Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers.

Price C, Gill S, Ho ZV, Davidson SM, Merkel E, McFarland JM, Leung L, Tang A, Kost-Alimova M, Tsherniak A, Jonas O, Vazquez F, Hahn WC.

Cancer Res. 2019 May 15;79(10):2564-2579. doi: 10.1158/0008-5472.CAN-18-2674. Epub 2019 Mar 21.

PMID:
30898838
6.

In vivo detection of drug-induced apoptosis in tumors using Raman spectroscopy.

Jonas O, Kang JW, Singh SP, Lammers A, Nguyen FT, Dasari RR, So PTC, Langer R, Cima MJ.

Analyst. 2018 Oct 8;143(20):4836-4839. doi: 10.1039/c8an00913a.

7.

Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.

Arai S, Jonas O, Whitman MA, Corey E, Balk SP, Chen S.

Clin Cancer Res. 2018 Nov 1;24(21):5458-5470. doi: 10.1158/1078-0432.CCR-18-0549. Epub 2018 Jul 18.

PMID:
30021909
8.

Call for independent monitoring of disease outbreak preparedness.

Jonas O, Katz R, Yansen S, Geddes K, Jha A.

BMJ. 2018 May 24;361:k2269. doi: 10.1136/bmj.k2269. No abstract available.

PMID:
29794069
9.

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.

Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, Thompson W, Smith R, Nederlof M, Bucher E, Kilburn D, Whitman M, Sudar D, Mills GB, Heiser LM, Jonas O, Gray JW, Korkola JE.

Cell Syst. 2018 Mar 28;6(3):329-342.e6. doi: 10.1016/j.cels.2018.02.001. Epub 2018 Mar 14.

10.

One Health Economics to confront disease threats.

Machalaba C, Smith KM, Awada L, Berry K, Berthe F, Bouley TA, Bruce M, Cortiñas Abrahantes J, El Turabi A, Feferholtz Y, Flynn L, Fournié G, Andre A, Grace D, Jonas O, Kimani T, Le Gall F, Miranda JJ, Peyre M, Pinto J, Ross N, Rüegg SR, Salerno RH, Seifman R, Zambrana-Torrelio C, Karesh WB.

Trans R Soc Trop Med Hyg. 2017 Jun 1;111(6):235-237. doi: 10.1093/trstmh/trx039.

11.

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R.

Science. 2017 Sep 15;357(6356):1156-1160. doi: 10.1126/science.aah5043.

12.

Synergistic interactions with PI3K inhibition that induce apoptosis.

Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang HT, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, Letai A, Root DE, Langer RS, Gray N, Hahn WC.

Elife. 2017 May 31;6. pii: e24523. doi: 10.7554/eLife.24523.

13.

Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors.

Davidson SM, Jonas O, Keibler MA, Hou HW, Luengo A, Mayers JR, Wyckoff J, Del Rosario AM, Whitman M, Chin CR, Condon KJ, Lammers A, Kellersberger KA, Stall BK, Stephanopoulos G, Bar-Sagi D, Han J, Rabinowitz JD, Cima MJ, Langer R, Vander Heiden MG.

Nat Med. 2017 Feb;23(2):235-241. doi: 10.1038/nm.4256. Epub 2016 Dec 26.

14.

MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.

Oudin MJ, Barbier L, Schäfer C, Kosciuk T, Miller MA, Han S, Jonas O, Lauffenburger DA, Gertler FB.

Mol Cancer Ther. 2017 Jan;16(1):143-155. doi: 10.1158/1535-7163.MCT-16-0413. Epub 2016 Nov 3.

15.

Integrated genetic and pharmacologic interrogation of rare cancers.

Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, Doshi MB, Oh C, Meyer SC, Church AJ, Gill S, Bielski CM, Keskula P, Imamovic A, Howell S, Kryukov GV, Clemons PA, Tsherniak A, Vazquez F, Crompton BD, Shamji AF, Rodriguez-Galindo C, Janeway KA, Roberts CW, Stegmaier K, van Hummelen P, Cima MJ, Langer RS, Garraway LA, Schreiber SL, Root DE, Hahn WC, Boehm JS.

Nat Commun. 2016 Jun 22;7:11987. doi: 10.1038/ncomms11987.

16.

First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development.

Jonas O, Calligaris D, Methuku KR, Poe MM, Francois JP, Tranghese F, Changelian A, Sieghart W, Ernst M, Krummel DA, Cook JM, Pomeroy SL, Cima M, Agar NY, Langer R, Sengupta S.

J Biomed Nanotechnol. 2016 Jun;12(6):1297-302.

17.

Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.

Jonas O, Oudin MJ, Kosciuk T, Whitman M, Gertler FB, Cima MJ, Flaherty KT, Langer R.

Clin Cancer Res. 2016 Dec 15;22(24):6031-6038. Epub 2016 Apr 18.

18.

Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.

Oudin MJ, Jonas O, Kosciuk T, Broye LC, Guido BC, Wyckoff J, Riquelme D, Lamar JM, Asokan SB, Whittaker C, Ma D, Langer R, Cima MJ, Wisinski KB, Hynes RO, Lauffenburger DA, Keely PJ, Bear JE, Gertler FB.

Cancer Discov. 2016 May;6(5):516-31. doi: 10.1158/2159-8290.CD-15-1183. Epub 2016 Jan 25.

19.

An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.

Jonas O, Landry HM, Fuller JE, Santini JT Jr, Baselga J, Tepper RI, Cima MJ, Langer R.

Sci Transl Med. 2015 Apr 22;7(284):284ra57. doi: 10.1126/scitranslmed.3010564.

20.

Force propagation and force generation in cells.

Jonas O, Duschl C.

Cytoskeleton (Hoboken). 2010 Sep;67(9):555-63. doi: 10.1002/cm.20466.

PMID:
20607861
21.

Development of a novel probe for measuring drug binding to the F1*S variant of human alpha 1-acid glycoprotein.

Cogswell LP 3rd, Raines DE, Parekh S, Jonas O, Maggio JE, Strichartz GR.

J Pharm Sci. 2001 Sep;90(9):1407-23.

PMID:
11745793
22.

Breech presentation in South Australia, 1987-1989.

Jonas O, Roder D.

Aust N Z J Obstet Gynaecol. 1993 Feb;33(1):17-21.

PMID:
8498932
25.

Pregnancy outcomes in primigravid women aged 35 years and over in South Australia, 1986-1988.

Jonas O, Chan A, Roder D, Macharper T.

Med J Aust. 1991 Feb 18;154(4):246-9.

PMID:
1994197
26.
27.

Pregnancy and birth risk factors for intellectual disability in South Australia.

Jonas O, Roder D, Esterman A, Macharper T, Chan A.

Eur J Epidemiol. 1989 Sep;5(3):322-7.

PMID:
2792308
28.

Caesarean section in South Australia, 1986.

Jonas O, Chan A, MacHarper T.

Aust N Z J Obstet Gynaecol. 1989 May;29(2):99-106.

PMID:
2803135
29.

A South Australian study of pregnancy and birth risk factors associated with cerebral palsy.

Jonas O, Stern LM, Macharper T.

Int J Rehabil Res. 1989;12(2):159-66.

PMID:
2625375
30.

ipecacuanha-ipecauanha.

Jonas O, Smyth N.

Med J Aust. 1975 Apr 26;1(17):534-5.

PMID:
239305
31.

A study of patients attending the casualty department of a paediatric hospital.

Jonas O.

Med J Aust. 1974 Jun 8;1(23):934-7. No abstract available.

PMID:
4850321
32.

Ceroid storage in a child with a Niemann-Pick type syndrome.

Jonas O.

Med J Aust. 1966 Sep 17;2(12):551-4. No abstract available.

PMID:
5922340
33.

[Regional organization of prenatal care].

JONAS O.

Prakt Lek. 1951 Jul 5;31(13-14):303-4. Undetermined Language. No abstract available.

PMID:
14875613

Supplemental Content

Support Center